SELDI-TOF-MS-based serum proteomic screening in combination with CT scan distinguishes renal cell carcinoma from benign renal tumors and healthy persons

Technology in Cancer Research and Treatment

Volumn 8, Issue 3, 2009, Pages 225-230

  Xu, Gang ^a   Cui, Qin Xiang ^b   Lu, Ye ^b   Wen, Jing Wang ^a   Xiao, Nan Kang ^a   Liao, Ping ^b   Ding, Qiang ^a   Yuan, Fang Zhang ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Diagnosis; Proteomics; Renal cell carcinoma; Serum

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DECISION TREE; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN MICROARRAY; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 66049156589     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460900800307     Document Type: Article

References (19)

1. Landis, S. H., Murray, T., Bolden, S., Wingo, P. A. Cancer statistics. CA Cancer J Clin 49, 8-31(1999).
2. Weiss, R. H., Lin, P. Y. Kidney cancer: identification of novel targets for therapy. Kidney Int 69, 224-232 (2006).
3. Pantuck, A. J., Zisman, A., Belldegrun, A. S. The changing natural history of renal cell carcinoma. J Urol 166, 1611-1623 (2001).
4. Berrington de Gonzalez, A., Darby, S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 363, 345-351(2004) (Pubitemid 38169539)
5. Zhang, Z., Bast, R. C., Jr., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., Rosenzweig, J. M., Cameron, B., Wang, Y. Y., Meng, X. Y., Berchuck, A., Van Haaften-Day, C., Hacker, N. F., de Bruijn, H. W., van der Zee, A. G., Jacobs, I. J., Fung, E. T., Chan, D. W. Three biomarkers identi- fied from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64, 5882-5890 (2004). (Pubitemid 39095590)
6. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., Chan, D. W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48, 1296-1304(2002)
7. Adam, B. L., Qu, Y., Davis, J. W., Ward, M. D., Clements, M. A., Cazares, L. H., Semmes, O. J., Schellhammer, P. F., Yasui, Y., Feng, Z., Wright, G. L., Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62, 3609-3614( 2002). (Pubitemid 34728833)
8. Chen, Y. D., Zheng, S., Yu, J. K., Hu, X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 10, 8380-8385 (2004). (Pubitemid 40053400)
9. Tolson, J., Bogumil, R., Brunst, E., Beck, H., Elsner, R., Humeny, A., Kratzin, H., Deeg, M., Kuczyk, M., Mueller, G. A., Mueller, C. A., Flad, T. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84, 845-856 (2004). (Pubitemid 38833244)
10. Won, Y., Song, H. J., Kang, T. W., Kim, J. J., Han, B. D., Lee, S. W. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 3, 2310-2316 (2003). (Pubitemid 38010108)
11. Hara, T., Honda, K., Ono, M., Naito, K., Hirohashi, S., Yamada, T. Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry. J Urol 174, 1213-1217 (2005). (Pubitemid 41318684)
12. Silverman, S. G., Mortele, K. J., Tuncali, K., Jinzaki, M., Cibas, E. S. Hyperattenuating renal masses: etiologies, pathogenesis, and imaging evaluation. Radiographics 27, 1131-1143 (2007).
13. Remzi, M., Katzenbeisser, D., Waldert, M., Klingler, H. C., Susani, M., Memarsadeghi, M., Heinz-Peer, G., Haitel, A., Herwig, R., Marberger, M. Renal tumour size measured radiologically before surgery is an unreliable variable for predicting histopathological features: benign tumours are not necessarily small. BJU Int 99, 1002-1006 (2007) (Pubitemid 46587912)
14. Ye, B., Cramer, D. W., Skates, S. J., Gygi, S. P., Pratomo, V., Fu, L., Horick, N. K., Licklider, L. J., Schorge, J. O., Berkowitz, R. S., Mok, S. C. Hepatoglobin-αsubunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9, 2904-2911 (2003). (Pubitemid 36993248)
15. Le, L., Chi, K., Tyldesley, S., Flibotte, S., Diamond, D. L., Kuzyk, M. A., Sadar, M. D. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51, 695-707 (2005). (Pubitemid 40463921)
16. Moshkovskii, S. A., Serebryakova, M. V., Kuteykin-Teplyakov, K. B., Tikhonova, O. V., Goufman, E. I., Zgoda, V. G., Taranets, I. N., Makarov, O. V., Archakov, A. I. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 5, 3790-3797 (2005).
17. Cho, W. C., Yip, T. T., Yip, C., Yip, V., Thulasiraman, V., Ngan, R. K., Yip, T. T., Lau, W. H., Au, J. S., Law, S. C., Cheng, W. W., Ma, V. W., Lim, C. K. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10, 43-52 (2004). (Pubitemid 38114160)
18. Diamandis, E. P. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 49, 1272-1275 (2003).
19. Pahernik, S., Ziegler, S., Roos, F., Melchior, S. W., Thüroff, J. W. Small renal tumors: correlation of clinical and pathological features with tumor size. J Urol 178, 414-417 (2007). (Pubitemid 47030507)